NCT06607185 2026-03-13A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsEli Lilly and CompanyPhase 1 Active not recruiting750 enrolled
NCT04430738 2026-02-24Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal CancersSeagen Inc.Phase 2 Active not recruiting40 enrolled 67 charts
NCT04421820 2026-01-27BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid TumoursBold Therapeutics, Inc.Phase 1/2 Recruiting220 enrolled
NCT07328919 2026-01-09Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or MutationsTransThera Sciences (Nanjing), Inc.Phase 3 Not yet recruiting138 enrolled
NCT03929666 2025-09-12A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal CancerJazz PharmaceuticalsPhase 2 Completed74 enrolled